FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214237298> ?p ?o ?g. }

• W3214237298 endingPage "e003195" @default.
• W3214237298 startingPage "e003195" @default.
• W3214237298 abstract "Background Immune checkpoint inhibitors (ICIs) have been shown to be a promising and effective treatment for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, there is a lack of evidence-based data demonstrating the impact of ICIs on HBV DNA level in HBV-HCC patients undergoing nucleos(t)ide analog (NA) therapy and of HBV DNA variation on patient survival. In this study, we aimed to investigate this issue in the real world. Methods In this single-center retrospective study, we reviewed 182 baseline hepatitis B surface antigen (HBsAg)-positive HBV-HCC patients who were treated with ICIs and pre-emptive NAs. The demographic characteristics, tumor status, treatments, HBV DNA, HBsAg, liver function, antitumor response, and patient survival were investigated. The primary endpoints were the virological breakthrough (VB) rate, HBV reactivation (HBVr) rate, and long-term HBV DNA control; the secondary endpoints were the overall survival (OS) and progression-free survival (PFS). Results (1) VB and HBVr occurred in 18.1% (33/182) and 4.4% (8/182) of patients with a median occurrence time of 3.9 months (range, 0.7–16.0) and 8.0 months (range, 3.0–16.0), respectively. The HBV DNA negative rates were 26.1% and 0 at 24 and 48 weeks in the VB group and 12.5% and 0 in the HBVr group, respectively. A baseline HBsAg level ≥200 IU/mL was the only risk factor for VB (OR 9.9, 95% CI 2.2 to 45.2, p=0.003); (2) patients with VB had much shorter median OS and median PFS than those without (12.3 months vs 18.1 months, p=0.035; 4.5 months vs 7.5 months, p=0.011). Conclusions There was a high risk of VB and a moderate risk of HBVr in HBsAg-positive HBV-HCC patients (with poor long-term HBV DNA control) undergoing ICI and pre-emptive NA therapies. The only risk factor for VB was the pretreatment HBsAg level. Further, VB might be considered as a clinical biomarker predicting inferior OS and PFS in the patients." @default.
• W3214237298 created "2021-11-22" @default.
• W3214237298 creator A5005426971 @default.
• W3214237298 creator A5010234420 @default.
• W3214237298 creator A5050787253 @default.
• W3214237298 creator A5063481044 @default.
• W3214237298 creator A5070662281 @default.
• W3214237298 creator A5085645609 @default.
• W3214237298 date "2021-11-01" @default.
• W3214237298 modified "2023-09-29" @default.
• W3214237298 title "Virological breakthrough after immune checkpoint inhibitor and nucleos(t)ide analog treatment in patients with hepatitis B surface antigen positive hepatocellular carcinoma: a real-world study" @default.
• W3214237298 cites W1752735880 @default.
• W3214237298 cites W1925864442 @default.
• W3214237298 cites W1977303859 @default.
• W3214237298 cites W1981611306 @default.
• W3214237298 cites W1983251878 @default.
• W3214237298 cites W2012007321 @default.
• W3214237298 cites W2026273466 @default.
• W3214237298 cites W2077518519 @default.
• W3214237298 cites W2079003449 @default.
• W3214237298 cites W2090407934 @default.
• W3214237298 cites W2097855813 @default.
• W3214237298 cites W2109485845 @default.
• W3214237298 cites W2115686439 @default.
• W3214237298 cites W2119190881 @default.
• W3214237298 cites W2222056650 @default.
• W3214237298 cites W2277004004 @default.
• W3214237298 cites W2507136820 @default.
• W3214237298 cites W2547391316 @default.
• W3214237298 cites W2559382297 @default.
• W3214237298 cites W2590941489 @default.
• W3214237298 cites W2606367731 @default.
• W3214237298 cites W2627067328 @default.
• W3214237298 cites W2747774814 @default.
• W3214237298 cites W2754081264 @default.
• W3214237298 cites W2761031851 @default.
• W3214237298 cites W2791839818 @default.
• W3214237298 cites W2796067155 @default.
• W3214237298 cites W2805592007 @default.
• W3214237298 cites W2905898293 @default.
• W3214237298 cites W2957852424 @default.
• W3214237298 cites W2989703635 @default.
• W3214237298 cites W2990602950 @default.
• W3214237298 cites W3004284786 @default.
• W3214237298 cites W3005196371 @default.
• W3214237298 cites W3008514541 @default.
• W3214237298 cites W3025022288 @default.
• W3214237298 cites W3081638078 @default.
• W3214237298 cites W3081945916 @default.
• W3214237298 cites W3090413519 @default.
• W3214237298 cites W3092757581 @default.
• W3214237298 cites W3093964219 @default.
• W3214237298 cites W3100629716 @default.
• W3214237298 cites W3152761256 @default.
• W3214237298 cites W4210955410 @default.
• W3214237298 cites W4239743462 @default.
• W3214237298 doi "https://doi.org/10.1136/jitc-2021-003195" @default.
• W3214237298 hasPublicationYear "2021" @default.
• W3214237298 type Work @default.
• W3214237298 sameAs 3214237298 @default.
• W3214237298 citedByCount "3" @default.
• W3214237298 countsByYear W32142372982022 @default.
• W3214237298 countsByYear W32142372982023 @default.
• W3214237298 crossrefType "journal-article" @default.
• W3214237298 hasAuthorship W3214237298A5005426971 @default.
• W3214237298 hasAuthorship W3214237298A5010234420 @default.
• W3214237298 hasAuthorship W3214237298A5050787253 @default.
• W3214237298 hasAuthorship W3214237298A5063481044 @default.
• W3214237298 hasAuthorship W3214237298A5070662281 @default.
• W3214237298 hasAuthorship W3214237298A5085645609 @default.
• W3214237298 hasBestOaLocation W32142372981 @default.
• W3214237298 hasConcept C126322002 @default.
• W3214237298 hasConcept C143998085 @default.
• W3214237298 hasConcept C159047783 @default.
• W3214237298 hasConcept C203014093 @default.
• W3214237298 hasConcept C2522874641 @default.
• W3214237298 hasConcept C2777382497 @default.
• W3214237298 hasConcept C2777410769 @default.
• W3214237298 hasConcept C2778019345 @default.
• W3214237298 hasConcept C2780593183 @default.
• W3214237298 hasConcept C71924100 @default.
• W3214237298 hasConcept C90924648 @default.
• W3214237298 hasConceptScore W3214237298C126322002 @default.
• W3214237298 hasConceptScore W3214237298C143998085 @default.
• W3214237298 hasConceptScore W3214237298C159047783 @default.
• W3214237298 hasConceptScore W3214237298C203014093 @default.
• W3214237298 hasConceptScore W3214237298C2522874641 @default.
• W3214237298 hasConceptScore W3214237298C2777382497 @default.
• W3214237298 hasConceptScore W3214237298C2777410769 @default.
• W3214237298 hasConceptScore W3214237298C2778019345 @default.
• W3214237298 hasConceptScore W3214237298C2780593183 @default.
• W3214237298 hasConceptScore W3214237298C71924100 @default.
• W3214237298 hasConceptScore W3214237298C90924648 @default.
• W3214237298 hasIssue "11" @default.
• W3214237298 hasLocation W32142372981 @default.
• W3214237298 hasLocation W32142372982 @default.
• W3214237298 hasLocation W32142372983 @default.
• W3214237298 hasOpenAccess W3214237298 @default.

• next